Experimental and Molecular Medicine Impact Factor

That places EMM in roughly the top 5% of its JCR category by current rank.

The useful signal here is the combination of a 17.5 JIF and a 17.8 five-year JIF. That tells you the journal's better papers are not just catching a short translational buzz cycle. They keep getting used because they remain relevant at the disease-mechanism level.

The journal's identity matters too. EMM occupies a specific lane: mechanistic biomedical work with a credible disease or therapeutic consequence. It is not a pure basic-science journal, and it is not a clinical outcomes journal either.

That is why the number can feel higher than authors expect for a journal that lives between those worlds. The journal is strong precisely because it does that middle lane well.

The author-planning implication is straightforward: EMM is rarely won by a metric-matching argument alone. A manuscript has to show why the mechanism changes disease understanding, why the model is credible for that disease context, and why the translational consequence is proportionate to the data. If those three pieces are separated across the introduction, results, and discussion, the impact factor can make the target look cleaner than it is.

The JCR row above is the authoritative impact factor on this page. Use the Scopus impact-score sequence below as an open-citation context check for EMM's translational molecular-medicine readership.

Directionally, the open citation signal is up from 9.18 in 2023 to 12.18 in 2024, and dramatically above the mid-2010s range. That is consistent with a journal that has become more visible as translational and disease-relevant molecular work has become more competitive.

The trend is not perfectly smooth. But the broader line is clear: EMM's citation position is substantially stronger than it was a decade ago.

The table below separates the current JCR placement from older public rank context. Do not treat older category ranks as the current official rank; use them only to understand why snippets and directories may disagree.

The common mistake is to read the JIF and assume EMM will take any clean mechanistic paper if the biology is interesting enough.

That is usually not the real bar. EMM works best when the manuscript connects:

• a molecular mechanism

• a disease or pathophysiology problem

• a believable translational consequence

• a package strong enough to survive outside a narrow specialty niche

If the disease relevance is generic, or the translational angle is mostly aspirational, the fit often weakens quickly.

Across our Experimental & Molecular Medicine pre-submission reviews, the recurring problem is not lack of science. It is lack of a clean translational story. Authors often have a mechanism, a disease context, and a hopeful implication, but the manuscript still reads like three parallel claims rather than one integrated argument. EMM usually rewards papers where disease meaning is explicit from the title, abstract, model choice, and first main figure.

Four failure patterns recur.

Experimental & Molecular Medicine omics signal without experimental follow-through. The associations may be strong, but the causal bridge is still too thin. In EMM-targeted drafts, this often shows up as a transcriptomic or proteomic figure that dominates the Results while the functional validation is a short final panel. The methods may be clean, but the abstract starts sounding like a biomarker paper rather than a disease-mechanism paper. Before submission, the main figure set should show what was perturbed, what changed biologically, and why that change matters for the disease model.

Experimental & Molecular Medicine disease framing that stays generic. The manuscript names a disease context without showing why the finding changes disease understanding or therapeutic logic. We see this most often when the introduction uses broad prevalence language, then the Results section never returns to a specific patient subgroup, disease stage, tissue context, or model limitation. EMM readers need the disease claim to survive contact with the methods, not just the final discussion paragraph.

Experimental & Molecular Medicine therapeutic language that outruns the data. This is common when a mechanism paper starts making treatment claims before the validation package justifies them. The cover letter may promise a therapeutic route, while the manuscript only shows pathway association, cell-line rescue, or a limited animal signal. For EMM, the safer version is usually a proportionate translational claim: what the result changes about target logic, patient stratification, or disease mechanism, and what validation still remains.

Experimental & Molecular Medicine story breadth without a sharp throughline. EMM usually prefers a clearer disease-mechanism-translational throughline than manuscripts first arrive with. A draft can have multiple datasets, several supplementary tables, and a plausible disease problem, yet still fail because the title, abstract, first Results subsection, and concluding paragraph each imply a slightly different center of gravity. The fix is not more claims. It is choosing one mechanism-to-disease argument and making every major figure serve it.

If that still sounds like the paper, an Experimental and Molecular Medicine submission readiness check is usually more valuable than cosmetic revision.

The impact factor does not tell you whether the translational bridge in your paper is convincing. EMM still expects the disease consequence to feel earned, not decorated. A mechanistic result plus a paragraph about therapeutic promise is often not enough.

That is where many submissions get misread by their own authors. The citation profile makes the journal look broadly permissive. In practice, the journal is selective about whether mechanism, disease meaning, and translational consequence form one coherent story.

That distinction becomes especially visible on papers built around one attractive dataset but an underdeveloped biomedical argument.

Experimental and Molecular Medicine has an impact factor of 17.5 and a five-year JIF of 17.8. The better signal is the journal's strengthened long-run citation profile in translational biomedical work.

If the disease relevance is still generic, the metric will make the fit look cleaner than it really is.

Already submitted? The Experimental & Molecular Medicine Under Review status guide explains what the current status means and when a follow-up is appropriate.